Robert Sinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Sinto has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Erni Juwita Nelwan
Division of Tropical Medicine and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
11 shared publications - Raph Leonardus Hamers
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
5 shared publications Suhendro Suwarto
Division of Tropical and Infectious Diseases, Department of Internal Medicine, Cipto Mangunkusumo National Hospital, Faculty of Medicine Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia
4 shared publicationsDjoko Widodo
Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Hospital, Jakarta Pusat, DKI Jakarta, Indonesia
3 shared publications- Khie Chen Lie
Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia and Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
3 shared publications - Susanna Dunachie
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
3 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Elsevier in SSRN Electronic Journal
Immunogenicity of IndoVac, a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, as a fifth-dose booster, compared with prior mRNA vaccine boosters: a longitudinal cohort study in Indonesian healthcare workers
Objectives Immunogenicity of IndoVac (BioFarma), a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, has not been well-studied. We evaluated fifth-dose IndoVac, following third- and fourth-dose mRNA vaccination, among Indonesian healthcare workers (HCWs). Methods Between August 2023 and January 2025, we measured anti-S-RBD IgG titres, neutralising antibody (nAb) titres against six Omicron-subvariants, and IFN-γ T-cell responses, before and 28 days after vaccine dose 3-5 in 30 HCWs. Results Anti-S-RBD IgG and nAb titres increased after third-dose mRNA vaccine (34.7-fold and 28.4–61.9-fold, respectively) and increased further after fourth-dose mRNA vaccine (4.2-fold and 4.8–6.8-fold, respectively), whereas fifth-dose IndoVac did not further improve antibody titres (1.3-fold and 1.9–4.1-fold decline, respectively). nAb titres against XBB-subvariants were consistently lower than against ancestral-strain. IFN-γ T-cell responses were detectable in most individuals after respective third, fourth, and fifth doses, both against ancestral-strain (91.7%, 100%, and 90.0%) and Omicron BA 2.86 (66.7%, 100%, and 100%). T-cell responses increased 3.6-fold after third-dose and remained stable thereafter. Conclusions Compared to immunogenic mRNA booster, IndoVac did not boost humoral or cellular immune responses against ancestral and Omicron-subvariants. These findings support efforts to advance domestic vaccine manufacturing capacity in LMICs, to ensure vaccine formulations can effectively target emerging SARS-CoV-2 variants.
- 18 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImmunogenicity of IndoVac, a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, as a fifth-dose booster, compared with prior mRNA vaccine boosters: a longitudinal cohort study in Indonesian healthcare workers
Objectives Immunogenicity of IndoVac (BioFarma), a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, has not been well-studied. We evaluated fifth-dose IndoVac, following third- and fourth-dose mRNA vaccination, among Indonesian healthcare workers (HCWs). Methods Between August 2023 and January 2025, we measured anti-S-RBD IgG titres, neutralising antibody (nAb) titres against six Omicron-subvariants, and IFN-γ T-cell responses, before and 28 days after vaccine dose 3-5 in 30 HCWs. Results Anti-S-RBD IgG and nAb titres increased after third-dose mRNA vaccine (34.7-fold and 28.4–61.9-fold, respectively) and increased further after fourth-dose mRNA vaccine (4.2-fold and 4.8–6.8-fold, respectively), whereas fifth-dose IndoVac did not further improve antibody titres (1.3-fold and 1.9–4.1-fold decline, respectively). nAb titres against XBB-subvariants were consistently lower than against ancestral-strain. IFN-γ T-cell responses were detectable in most individuals after respective third, fourth, and fifth doses, both against ancestral-strain (91.7%, 100%, and 90.0%) and Omicron BA 2.86 (66.7%, 100%, and 100%). T-cell responses increased 3.6-fold after third-dose and remained stable thereafter. Conclusions Compared to immunogenic mRNA booster, IndoVac did not boost humoral or cellular immune responses against ancestral and Omicron-subvariants. These findings support efforts to advance domestic vaccine manufacturing capacity in LMICs, to ensure vaccine formulations can effectively target emerging SARS-CoV-2 variants.
- Open Access
Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
- Open Access
- 22 November 2024
- Published by MDPI AG in Preprints.org
Epidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
- 22 November 2024
- Published by MDPI AG in Preprints.org
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
- Open Access
- 18 October 2024
- Published by Elsevier in Journal of Hospital Infection
- Vol. 154, 77-87
A nationwide mixed-methods study of gaps and barriers to implementation of antimicrobial stewardship programmes in hospitals in Indonesia
- 18 October 2024
- Published by Elsevier in Journal of Hospital Infection
- Vol. 154, 77-87
Open AccessA nationwide mixed-methods study of gaps and barriers to implementation of antimicrobial stewardship programmes in hospitals in Indonesia
- Open Access
- 12 September 2024
- Published by MDPI AG in Infectious Disease Reports
- Vol. 16 (5) , 894-905
Obesity Parameters as Predictor of Poor Outcomes in Hospitalized Patients with Confirmed Mild-to-Moderate COVID-19
(1) Background: This study aims to assess visceral fat values, waist circumference (WC), body mass index (BMI), and body fat percentage for their ability to predict poor outcomes during COVID-19 patients’ hospitalization; (2) Methods: This study was a prospective cohort of mild–moderate COVID-19 patients hospitalized at Dr. Cipto Mangunkusumo National General Hospital from December 2020 to March 2021. This study includes hospitalized patients over 18 diagnosed with COVID-19 using RT-PCR. Patients who do not have chest radiography, waist circumference, a bioimpedance analyzer (BIA) error, or are unable to stand or mobilize during the examination are excluded from this study. Cox regression was used for multivariate analysis; (3) Results: The study included two hundred sixty-one patients. The median visceral fat value was 10 (equivalent to 100 cm2), the WC was 93.4 cm, the BMI was 26.1 kg/m2, and the body fat percentage was 31.5%. Based on multivariate Cox regression, WC was statistically significant as an independent factor influencing poor outcomes in COVID-19 patients (RR 1.037 [95% CI 1.011–1.064]) along with COVID-19 degree of severity (RR 3.063 [95% CI 1.537–6.104]) and comorbidities (RR 2.123 [95% CI 1.017–4.435]); (4) Conclusions: Waist circumference can influence poor outcomes in confirmed COVID-19 patients during hospitalization.
- 12 September 2024
- Published by MDPI AG in Infectious Disease Reports
- Vol. 16 (5) , 894-905
Open AccessObesity Parameters as Predictor of Poor Outcomes in Hospitalized Patients with Confirmed Mild-to-Moderate COVID-19
(1) Background: This study aims to assess visceral fat values, waist circumference (WC), body mass index (BMI), and body fat percentage for their ability to predict poor outcomes during COVID-19 patients’ hospitalization; (2) Methods: This study was a prospective cohort of mild–moderate COVID-19 patients hospitalized at Dr. Cipto Mangunkusumo National General Hospital from December 2020 to March 2021. This study includes hospitalized patients over 18 diagnosed with COVID-19 using RT-PCR. Patients who do not have chest radiography, waist circumference, a bioimpedance analyzer (BIA) error, or are unable to stand or mobilize during the examination are excluded from this study. Cox regression was used for multivariate analysis; (3) Results: The study included two hundred sixty-one patients. The median visceral fat value was 10 (equivalent to 100 cm2), the WC was 93.4 cm, the BMI was 26.1 kg/m2, and the body fat percentage was 31.5%. Based on multivariate Cox regression, WC was statistically significant as an independent factor influencing poor outcomes in COVID-19 patients (RR 1.037 [95% CI 1.011–1.064]) along with COVID-19 degree of severity (RR 3.063 [95% CI 1.537–6.104]) and comorbidities (RR 2.123 [95% CI 1.017–4.435]); (4) Conclusions: Waist circumference can influence poor outcomes in confirmed COVID-19 patients during hospitalization.
- 1 July 2024
- Vol. 56 (3) , 419-431
Re-Emerging Trend of Mpox Infection: The Indonesia's Experience and Review
Background: Since Monkeypox (mpox) had an outbreak on 6th May 2022 in 75 countries, it has been declared by the World Health Organization (WHO) that mpox is a public health of international emergency concern (PHEIC). WHO declared mpox as PHEIC again inAugust 204. Indonesia was also affected by the mpox outbreak with most of the cases coming from vulnerable populations. This study aimed to give an overview of mpox as well as the recent outbreak situation and management in Indonesia. Methods: In this narrative review (using PubMed, Scopus, and Cochrane databases combined with countries'national official reports and grey literatures), we discussed an overview of mpox including epidemiology, morphology, transmission, symptoms, treatment, and prevention. The management of mpox in Indonesia was specifically reviewed. Results: Mpox is an infectious disease caused by the mpox virus which has infected 79,231 individuals globally. In Indonesia, the first mpox case was detected in August 2022 with 0 deaths and 88 confirmed cases as ofAugust 2024. The virus is transmitted via respiratory droplets or direct contact with contaminated objects, surfaces, or mucocutaneous lesions of an infected individual which could lead to symptoms such as epidermal papules-pustules and clinical characteristics of classical smallpox. Although antivirals such as tecovirimat, cidofovir, and brincidofovir have been raised as potential treatments for mpox, these agents were only considered in severe cases in Indonesia. Conclusion: Mpox is a contagious disease that could cause major health problems if left uncontrolled, especially in specific vulnerable populations due to its high morbidity and mortality. Therefore, particular measures must be performed, especially in Indonesia.
- 1 July 2024
- Vol. 56 (3) , 419-431
Re-Emerging Trend of Mpox Infection: The Indonesia's Experience and Review
Background: Since Monkeypox (mpox) had an outbreak on 6th May 2022 in 75 countries, it has been declared by the World Health Organization (WHO) that mpox is a public health of international emergency concern (PHEIC). WHO declared mpox as PHEIC again inAugust 204. Indonesia was also affected by the mpox outbreak with most of the cases coming from vulnerable populations. This study aimed to give an overview of mpox as well as the recent outbreak situation and management in Indonesia. Methods: In this narrative review (using PubMed, Scopus, and Cochrane databases combined with countries'national official reports and grey literatures), we discussed an overview of mpox including epidemiology, morphology, transmission, symptoms, treatment, and prevention. The management of mpox in Indonesia was specifically reviewed. Results: Mpox is an infectious disease caused by the mpox virus which has infected 79,231 individuals globally. In Indonesia, the first mpox case was detected in August 2022 with 0 deaths and 88 confirmed cases as ofAugust 2024. The virus is transmitted via respiratory droplets or direct contact with contaminated objects, surfaces, or mucocutaneous lesions of an infected individual which could lead to symptoms such as epidermal papules-pustules and clinical characteristics of classical smallpox. Although antivirals such as tecovirimat, cidofovir, and brincidofovir have been raised as potential treatments for mpox, these agents were only considered in severe cases in Indonesia. Conclusion: Mpox is a contagious disease that could cause major health problems if left uncontrolled, especially in specific vulnerable populations due to its high morbidity and mortality. Therefore, particular measures must be performed, especially in Indonesia.
- Open Access
- 13 May 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 26, 100414
Antimicrobial resistance among common bacterial pathogens in Indonesia: a systematic review
- 13 May 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 26, 100414
Open AccessAntimicrobial resistance among common bacterial pathogens in Indonesia: a systematic review
- 1 April 2024
- Vol. 56 (2) , 199-205
Diagnostic Accuracy of Serum Procalcitonin to Diagnose Sepsis in Advanced Solid Tumor Patients with Fever
Background: Diagnosis of infection in advanced solid tumor patients can be challenging since signs and symptoms might be overlapping due to paraneoplastic condition. Delay diagnosis of existing infection can lead more severe conditions and increased mortality. Procalcitonin (PCT) has been used to support the diagnosis bacterial infection and sepsis. Unfortunately, PCT also increases in malignancy even without an infection. We investigated the diagnostic accuracy of PCT in advanced solid tumor patients with fever to diagnose sepsis. Methods: A cross-sectional study was conducted in solid advanced tumor patients with fever patients who were admitted to Cipto Mangunkusumo Hospitals, Indonesia between June 2016 and April 2018. Sepsis was defined using 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference criteria. The diagnostic accuracy of PCT was determined using the receiver operating characteristic (ROC) curve. Results: A total of 194 subjects were enrolled in this study. 60.3% were female with a mean age of 49.47 +/- 12.87 years old. 143 patients (73.7%) with advanced solid tumors. Among this latter group, 39 patients (27%) were sepsis. The ROC curve showed that the levels of PCT for sepsis in advanced solid tumor patients with fever were in the area under the curve (AUC) 0.853 (95%CI 0.785 - 0.921). The Cut-off of PCT in advanced solid tumor patients with fever to classify as sepsis was 2.87 ng/mL, with a sensitivity of 79.5%, and a specificity of 79.8%. Conclusion: PCT has good diagnosis accuracy in advanced solid tumor patients with fever to classify as sepsis, however a higher cut-off compared to non-cancerous patients should be used.
- 1 April 2024
- Vol. 56 (2) , 199-205
Diagnostic Accuracy of Serum Procalcitonin to Diagnose Sepsis in Advanced Solid Tumor Patients with Fever
Background: Diagnosis of infection in advanced solid tumor patients can be challenging since signs and symptoms might be overlapping due to paraneoplastic condition. Delay diagnosis of existing infection can lead more severe conditions and increased mortality. Procalcitonin (PCT) has been used to support the diagnosis bacterial infection and sepsis. Unfortunately, PCT also increases in malignancy even without an infection. We investigated the diagnostic accuracy of PCT in advanced solid tumor patients with fever to diagnose sepsis. Methods: A cross-sectional study was conducted in solid advanced tumor patients with fever patients who were admitted to Cipto Mangunkusumo Hospitals, Indonesia between June 2016 and April 2018. Sepsis was defined using 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference criteria. The diagnostic accuracy of PCT was determined using the receiver operating characteristic (ROC) curve. Results: A total of 194 subjects were enrolled in this study. 60.3% were female with a mean age of 49.47 +/- 12.87 years old. 143 patients (73.7%) with advanced solid tumors. Among this latter group, 39 patients (27%) were sepsis. The ROC curve showed that the levels of PCT for sepsis in advanced solid tumor patients with fever were in the area under the curve (AUC) 0.853 (95%CI 0.785 - 0.921). The Cut-off of PCT in advanced solid tumor patients with fever to classify as sepsis was 2.87 ng/mL, with a sensitivity of 79.5%, and a specificity of 79.8%. Conclusion: PCT has good diagnosis accuracy in advanced solid tumor patients with fever to classify as sepsis, however a higher cut-off compared to non-cancerous patients should be used.
- Open Access
- 7 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0297405
Diagnostic and antibiotic use practices among COVID-19 and non-COVID-19 patients in the Indonesian National Referral Hospital
Background: Little is known about diagnostic and antibiotic use practices in low and middle-income countries (LMICs) before and during COVID-19 pandemic. This information is crucial for monitoring and evaluation of diagnostic and antimicrobial stewardships in healthcare facilities. Methods: We linked and analyzed routine databases of hospital admission, microbiology laboratory and drug dispensing of Indonesian National Referral Hospital from 2019 to 2020. Patients were classified as COVID-19 cases if their SARS-CoV-2 RT-PCR result were positive. Blood culture (BC) practices and time to discontinuation of parenteral antibiotics among inpatients who received a parenteral antibiotic for at least four consecutive days were used to assess diagnostic and antibiotic use practices, respectively. Fine and Grey subdistribution hazard model was used. Results: Of 1,311 COVID-19 and 58,917 non-COVID-19 inpatients, 333 (25.4%) and 18,837 (32.0%) received a parenteral antibiotic for at least four consecutive days. Proportion of patients having BC taken within ±1 calendar day of parenteral antibiotics being started was higher in COVID-19 than in non-COVID-19 patients (21.0% [70/333] vs. 18.7% [3,529/18,837]; p<0.001). Cumulative incidence of having a BC taken within 28 days was higher in COVID-19 than in non-COVID-19 patients (44.7% [149/333] vs. 33.2% [6,254/18,837]; adjusted subdistribution-hazard ratio [aSHR] 1.71, 95% confidence interval [CI] 1.47–1.99, p<0.001). The median time to discontinuation of parenteral antibiotics was longer in COVID-19 than in non-COVID-19 patients (13 days vs. 8 days; aSHR 0.73, 95%Cl 0.65–0.83, p<0.001). Conclusions: Routine electronic data could be used to inform diagnostic and antibiotic use practices in LMICs. In Indonesia, the proportion of timely blood culture is low in both COVID-19 and non-COVID-19 patients, and duration of parenteral antibiotics is longer in COVID-19 patients. Improving diagnostic and antimicrobial stewardship is critically needed.
- 7 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0297405
Open AccessDiagnostic and antibiotic use practices among COVID-19 and non-COVID-19 patients in the Indonesian National Referral Hospital
Background: Little is known about diagnostic and antibiotic use practices in low and middle-income countries (LMICs) before and during COVID-19 pandemic. This information is crucial for monitoring and evaluation of diagnostic and antimicrobial stewardships in healthcare facilities. Methods: We linked and analyzed routine databases of hospital admission, microbiology laboratory and drug dispensing of Indonesian National Referral Hospital from 2019 to 2020. Patients were classified as COVID-19 cases if their SARS-CoV-2 RT-PCR result were positive. Blood culture (BC) practices and time to discontinuation of parenteral antibiotics among inpatients who received a parenteral antibiotic for at least four consecutive days were used to assess diagnostic and antibiotic use practices, respectively. Fine and Grey subdistribution hazard model was used. Results: Of 1,311 COVID-19 and 58,917 non-COVID-19 inpatients, 333 (25.4%) and 18,837 (32.0%) received a parenteral antibiotic for at least four consecutive days. Proportion of patients having BC taken within ±1 calendar day of parenteral antibiotics being started was higher in COVID-19 than in non-COVID-19 patients (21.0% [70/333] vs. 18.7% [3,529/18,837]; p<0.001). Cumulative incidence of having a BC taken within 28 days was higher in COVID-19 than in non-COVID-19 patients (44.7% [149/333] vs. 33.2% [6,254/18,837]; adjusted subdistribution-hazard ratio [aSHR] 1.71, 95% confidence interval [CI] 1.47–1.99, p<0.001). The median time to discontinuation of parenteral antibiotics was longer in COVID-19 than in non-COVID-19 patients (13 days vs. 8 days; aSHR 0.73, 95%Cl 0.65–0.83, p<0.001). Conclusions: Routine electronic data could be used to inform diagnostic and antibiotic use practices in LMICs. In Indonesia, the proportion of timely blood culture is low in both COVID-19 and non-COVID-19 patients, and duration of parenteral antibiotics is longer in COVID-19 patients. Improving diagnostic and antimicrobial stewardship is critically needed.
- Open Access
The Clinimetric Profile of 11 Generic Quality Indicators for Appropriate Antibiotic Use in Hospitalized Patients in Indonesia
Background: One of the efforts in antibiotic stewardship for limiting antibiotic resistance is the assessment of the quality of antibiotic use. To date, the quality and appropriateness of antibiotic use in Indonesia, a low-middle-income non-European country, have not yet been assessed using proven quality indicators (QIs). One recommended tool to measure appropriate empiric antibiotic use in hospitalized patients is the generic QIs reported by van den Bosch et. al ., which demonstrated good validity and generalizability. Objective: The aim of this study is to assess the clinimetric profile of 11 generic QIs based on van den Bosch et. al . in admitted adult patients receiving empiric antibiotics in Indonesian hospitals. Methods: This is an observational study with a cross-sectional design conducted at two government referral hospitals in Jakarta, Indonesia, from August 1, 2022, to February 2, 2023. Adult inpatients who received empiric antibiotics due to suspected infection for ≥24 hours were included in the study. Results: In 500 inpatients from 2 hospitals, all QIs demonstrated good measurability with less than 10% of missing data. Ten QIs showed good applicability of >10%. Four QIs show good performance, while six QIs have significant potential for improvement (two blood cultures are obtained before empiric antibiotic treatment; culture sample is obtained from location suspected of infection; antibiotic is switched from intravenous to oral when clinically possible; antibiotics are stopped when there is no evidence of infection; a guideline is available and renewed every three years; and a guideline is adjusted to the local resistance pattern) making them priority targets for interventions to enhance the quality of antibiotic use in Indonesia. All QIs display good inter-observer reliability, and no moderate or strong correlations are found between QIs. Conclusion: The clinimetric assessment of QIs is imperative before their implementation in any setting different from their country of origin. Of the 11 generic QIs, 10 demonstrated good reliability and applicability at two hospitals in Indonesia. Future intervention studies can utilize these generic QIs to measure improvement in the appropriateness of antibiotic use.
Open AccessThe Clinimetric Profile of 11 Generic Quality Indicators for Appropriate Antibiotic Use in Hospitalized Patients in Indonesia
Background: One of the efforts in antibiotic stewardship for limiting antibiotic resistance is the assessment of the quality of antibiotic use. To date, the quality and appropriateness of antibiotic use in Indonesia, a low-middle-income non-European country, have not yet been assessed using proven quality indicators (QIs). One recommended tool to measure appropriate empiric antibiotic use in hospitalized patients is the generic QIs reported by van den Bosch et. al ., which demonstrated good validity and generalizability. Objective: The aim of this study is to assess the clinimetric profile of 11 generic QIs based on van den Bosch et. al . in admitted adult patients receiving empiric antibiotics in Indonesian hospitals. Methods: This is an observational study with a cross-sectional design conducted at two government referral hospitals in Jakarta, Indonesia, from August 1, 2022, to February 2, 2023. Adult inpatients who received empiric antibiotics due to suspected infection for ≥24 hours were included in the study. Results: In 500 inpatients from 2 hospitals, all QIs demonstrated good measurability with less than 10% of missing data. Ten QIs showed good applicability of >10%. Four QIs show good performance, while six QIs have significant potential for improvement (two blood cultures are obtained before empiric antibiotic treatment; culture sample is obtained from location suspected of infection; antibiotic is switched from intravenous to oral when clinically possible; antibiotics are stopped when there is no evidence of infection; a guideline is available and renewed every three years; and a guideline is adjusted to the local resistance pattern) making them priority targets for interventions to enhance the quality of antibiotic use in Indonesia. All QIs display good inter-observer reliability, and no moderate or strong correlations are found between QIs. Conclusion: The clinimetric assessment of QIs is imperative before their implementation in any setting different from their country of origin. Of the 11 generic QIs, 10 demonstrated good reliability and applicability at two hospitals in Indonesia. Future intervention studies can utilize these generic QIs to measure improvement in the appropriateness of antibiotic use.